Answers are grounded in this paper and cite their sources.
Background Lung adenocarcinoma (LUAD), the most prevalent histological subtype of lung cancer, exhibits high recurrence and metastatic potential. Tumor-microenvironment angiogenesis is closely associated with LUAD progression, and cancer-associated fibroblasts (CAFs), a central stromal component of the tumor microenvironment, have been reported to contribute to protumor phenotypes. Owing to substantial CAF heterogeneity, how CAFs modulate tumor angiogenesis remains incompletely understood. This study integrated single-cell and bulk transcriptomic datasets to identify CAF-associated angiogenesis- associated genes, build a prognostic risk model for LUAD, and characterize the biological function of core gene SERPINH1. Methods Transcriptomic data and single-cell RNA sequencing data of LUAD samples from the TCGA and GEO databases were integrated for cell subpopulation annotation and angiogenic activity analysis. Differential expression analysis was performed on key cell subpopulations to construct a prognostic model associated with fibroblast-linked angiogenesis genes in LUAD. Univariate and multivariate Cox regression, LASSO regression, and Kaplan-Meier survival analysis were used to evaluate the prognostic value of candidate genes. Core genes were screened for further analyses of immune infiltration, tumor mutational burden, pathway enrichment, and drug sensitivity. Unsupervised clustering based on core gene expression was conducted to classify tumor subtypes, and in vitro experiments were performed to verify the functions of the core gene SERPINH1. Results Single-cell analyses demonstrated elevated angiogenic activity in tumor-resident fibroblasts relative to non-tumor fibroblasts. An eight-gene prognostic signature was constructed from 63 fibroblast-associated angiogenic genes. High-risk patients displayed worse clinical outcomes, higher mutation frequency, greater tumor purity, more immunosuppressive cell infiltration, and computational analyses suggested a potential, hypothesis-generating trend toward differential predicted sensitivity to immunotherapy, chemotherapy and targeted agents; these predictions require prospective clinical validation. Two molecular subtypes with distinct pathway profiles and TP53 mutation rates were identified. Knockdown of SERPINH1, which was highly expressed in high-risk samples and LUAD cell lines, reduced cell proliferation and colony formation, induced G0/G1 cell-cycle arrest, attenuated angiogenic activity in vitro , and was accompanied by decreased phosphorylation of AKT and NF-κB p65. Conclusions Collectively, in retrospective cohorts, our CAF-angiogenesis-associated risk model was associated with overall survival and yielded hypothesis-generating computational predictions of therapeutic-response trends in LUAD. High-risk cases exhibited immunosuppressive and high-mutation transcriptomic phenotypes. SERPINH1, supported by our in vitro findings, represents a candidate target warranting further mechanistic and in vivo validation before any clinical application.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: